# US 2022/0022457 A1 · Microbicide Ammonium-Imidazolium Oligomers and Their Anti-Fungal Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0022457 A1
- Document ID: US20220022457A1
- Status: Published application
- Kind: A1
- Application number: 17/276,866
- Filed: 2019-09-20
- Published: 2022-01-27
- Earliest claimed: 2018-09-20
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Yugen Zhang; Yuan Yuan
- Web page: https://patentgrep.com/patent/US20220022457A1

## CPC

- A01N 33/12: Quaternary ammonium compounds
- A01N 43/90: having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A01N 43/50: 1,3-Diazoles; Hydrogenated 1,3-diazoles
- A01N 43/60: 1,4-Diazines; Hydrogenated 1,4-diazines
- A01N 43/653: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 31/04: Antibacterial agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to compositions comprising an oligomer of Formula (I): having imidazolium and diammonium substituents; and an anti-fungal compound comprising at least one triazole group. The composition as described herein may be used as an anti-fungal composition for therapeutic and non-therapeutic applications.

## Claims

### Claim 1

A composition comprising:
an oligomer of Formula (I)
wherein R1 is in each instance, same or different, and is independently selected from the group consisting of:
R2 is independently selected from the group consisting of
wherein X, in each instance, is same or different, and is a halogen;
L is, in each instance, independently selected from the group consisting of: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted arylalkynyl, optionally substituted alkylaryl, optionally substituted alkenylaryl, and optionally substituted alkynylaryl;
E consists of between 2 to 20 carbon atoms and is independently selected from the group consisting of: optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted alkylaryl;
n is an integer of between 1 to 10; and
an anti-fungal agent comprising at least one triazole group.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein at least one R1 is

### Claim 3 (depends on 1)

The composition according to claim 1, wherein R2 is

### Claim 4 (depends on 1)

The composition according to claim 1, wherein E consists of between 6 to 12 carbon atoms and is independently, optionally substituted alkyl or optionally substituted aryl groups.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein E is a n-octyl group.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein L is in each instance independently selected from the group consisting of optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted arylalkenyl; and consists of between 2 to 20 carbon atoms.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein L is in each instance, independently selected from the group consisting of para-xylenyl, ortho-xylenyl and trans-2-butenyl.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein n is an integer from 1 to 5.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein n is 3.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the anti-fungal agent is selected from fluconazole, itraconazole, voriconazole or combinations thereof.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein the anti-fungal agent is fluconazole.

### Claim 12 (depends on 1)

The composition according to claim 1, wherein the weight ratio of the anti-fungal agent to the oligomer is from 1:1 to 1:1500.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein the oligomer is selected from the group consisting of:

### Claim 14 (depends on 1)

A method of treating microbial infections by administering the composition according to claim 1 to a subject in need thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the microbial infection is a fungal infection caused by a Candida fungi.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the fungi is Candida albicans.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the composition is administered at a concentration of 0.2 μg/ml-150 μg/ml.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the composition is administered at a concentration of 1.0-4.0 μg/ml.

### Claim 19 (depends on 1)

A method for killing or inhibiting microbial growth ex vivo, comprising a step of applying the composition according to claim 1.
